Pfiz­er bags an FDA OK for PARP play­er ta­la­zoparib — now the hard part be­gins

Pfiz­er has picked up an ap­proval for ta­la­zoparib, its PARP in­hibitor for a ge­net­i­cal­ly de­fined line of breast can­cer. And now the phar­ma play­er can jump in­to a crowd­ed mar­ket where As­traZeneca’s ri­val Lyn­parza is way out in front of the pack.

The Pfiz­er drug, which is hit­ting the mar­ket as Talzen­na, fig­ured promi­nent­ly in Pfiz­er’s $14 bil­lion Medi­va­tion buy­out. The then Medi­va­tion CEO David Hung pitched ta­la­zoparib as a block­buster-to-be as Sanofi stepped up first with an of­fer. Now Pfiz­er gets to find out just how much it can make as the fourth en­try in the field, be­hind Clo­vis and Tesaro as well.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.